Evidence map›Paper›PMID 34975328›Full record

ArticleInternational journal of biological sciences2022

PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.

Mu Yun, Li Yingzi, Gao Jie, Liu Guanxin, Zeng Zimei, Cao Zhen, Li Zhi, Nie Yingjie, Sun Lunquan, Chen Tao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mu YunDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Li YingziState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Gao JieDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Liu GuanxinState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Zeng ZimeiDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Cao ZhenDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Li ZhiDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Nie YingjieNHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital; Guiyang 550000, China.
Sun LunquanDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Chen TaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Deng YuezhenDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhou ChengzhiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Xiangya Hospital Central South University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNCentral South University · CNState Key Laboratory of Respiratory Disease · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to radiotherapy is frequently observed in the clinic and leads to poor prognosis of non-small cell lung cancer (NSCLC). How to overcome resistance to radiotherapy is a challenge in the treatment of NSCLC. In this study, PPDPF was found to be upregulated in NSCLC tissues and cell lines, and its expression negatively correlated with the overall survival of patients with NSCLC. PPDPF promoted the growth, colony formation and invasion of lung cancer cells. Moreover, knockout of PPDPF inhibited tumorigenesis in the KL (Kras

Indexed as

AnimalsApoptosis Regulatory ProteinsCarcinogenesisCarcinoma, Non-Small-Cell LungCell Line, TumorDisease ProgressionDown-RegulationHumansIntracellular Signaling Peptides and ProteinsLung NeoplasmsMiceMice, NudePrognosisUp-RegulationXenograft Model Antitumor AssaysApoptosis Regulatory ProteinsIntracellular Signaling Peptides and ProteinsPPDPF protein, humanBABAM2MDM2NSCLCPPDPFradioresistance

Identifiers

PMID34975328
PMCPMC8692159
OpenAlexW3213542757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.